[HTML][HTML] Virologic outcomes with molnupiravir in non-hospitalized adult patients with COVID-19 from the randomized, placebo-controlled MOVe-OUT trial
JM Strizki, JA Grobler, N Murgolo, A Fridman… - Infectious Diseases and …, 2023 - Springer
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
JM Strizki, JA Grobler, N Murgolo… - Infectious Diseases …, 2023 - europepmc.org
Methods Nasopharyngeal swabs were collected at baseline (day 1, prior to first dose) and
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
JM Strizki, JA Grobler, N Murgolo… - Infectious Diseases …, 2023 - search.proquest.com
Methods Nasopharyngeal swabs were collected at baseline (day 1, prior to first dose) and
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
JM Strizki, JA Grobler, N Murgolo… - Infectious diseases …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
[HTML][HTML] Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
JM Strizki, JA Grobler, N Murgolo… - Infectious Diseases …, 2023 - ncbi.nlm.nih.gov
Methods Nasopharyngeal swabs were collected at baseline (day 1, prior to first dose) and
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
days 3, 5 (end-of-treatment visit), 10, 15, and 29. From these samples, change from baseline …
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
JM Strizki, JA Grobler, N Murgolo… - … Diseases & Therapy, 2023 - search.ebscohost.com
Introduction: The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
JM Strizki, JA Grobler, N Murgolo, A Fridman… - … Diseases and Therapy, 2023 - go.gale.com
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …
[引用][C] Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
JM Strizki, JAGN Murgolo, AFMGJ Jiejun… - 2023 - europepmc.org
Introduction: The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800mg every 12h for 5days) as safe and effective for outpatient …
demonstrated molnupiravir (800mg every 12h for 5days) as safe and effective for outpatient …